PU.1 is a lineage-specific regulator of tyrosine phosphatase CD45

被引:28
作者
Anderson, KL
Nelson, SL
Perkin, HB
Smith, KA
Klemsz, MJ
Torbett, BE
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA
关键词
D O I
10.1074/jbc.M009133200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hematopoietic cell-specific ets family transcription factor PU.1 regulates many lymphoid and myeloid genes. We have determined that PU.1 is critical for lineage-specific expression of the tyrosine phosphatase CD45, CD45 is expressed exclusively in hematopoietic cells at all stages of development, except for mature red cells and platelets, Although CD45 is normally expressed in all leukocyte lineages, it is critically regulated by PU.1 only in myeloid cells. Whereas myeloid cells from PU.1 null mice failed to express CD45, lymphoid cells were CD45(+) by flow cytometry, Additionally, mRNA for CD45 was absent from PU.1-deficient myeloid cells. To understand the molecular basis for these observations, we characterized a transcriptional regulatory region of the murine CD45 gene containing exons 1a, 1b, and 2, Distinct transcriptional initiation sites for CD45 were demonstrated in T and B cells versus myeloid cells. A transcriptional initiation site in exon 1b (P1b) was principally utilized by myeloid cells. A PU.1 binding site was identified upstream of exon Ib by sequence analysis and DNA binding assays. Using this region of the CD45 locus we demonstrated that PU.1 directly transactivated reporter gene expression, Finally, retrovirus-mediated restoration of PU.1 expression to PU.1-deficient myeloid cells resulted in expression of cell surface CD45 and restored phosphatase activity, confirming the role of PU.1 in the positive regulation of this well known signaling molecule, We conclude that CD45 is regulated differentially in myeloid and lymphoid cells and that sequences critical to direct myeloid expression include a PU.1 binding site upstream of the P1b transcriptional initiation site.
引用
收藏
页码:7637 / 7642
页数:6
相关论文
共 36 条
  • [1] Myeloid development is selectively disrupted in PU.1 null mice
    Anderson, KL
    Smith, KA
    Conners, K
    McKercher, SR
    Maki, RA
    Torbett, BE
    [J]. BLOOD, 1998, 91 (10) : 3702 - 3710
  • [2] Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent
    Anderson, KL
    Smith, KA
    Pio, F
    Torbett, BE
    Maki, RA
    [J]. BLOOD, 1998, 92 (05) : 1576 - 1585
  • [3] PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation
    Anderson, KL
    Smith, KA
    Perkin, H
    Hermanson, G
    Anderson, CG
    Jolly, DJ
    Maki, RA
    Torbett, BE
    [J]. BLOOD, 1999, 94 (07) : 2310 - 2318
  • [4] CD45 and Src-family kinases: and now for something completely different
    Ashwell, JD
    D'Oro, U
    [J]. IMMUNOLOGY TODAY, 1999, 20 (09): : 412 - 416
  • [5] Spi-C, a novel Ets protein that is temporally regulated during B lymphocyte development
    Bemark, M
    Mårtensson, A
    Liberg, D
    Leanderson, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (15) : 10259 - 10267
  • [6] CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4(+)CD8(+) thymocytes, and in B cell maturation
    Byth, KF
    Conroy, LA
    Howlett, S
    Smith, AJH
    May, J
    Alexander, DR
    Holmes, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) : 1707 - 1718
  • [7] NEUTROPHILS AND MONOCYTES EXPRESS HIGH-LEVELS OF PU.1 (SPI-1) BUT NOT SPI-B
    CHEN, HM
    ZHANG, P
    VOSO, MT
    HOHAUS, S
    GONZALEZ, DA
    GLASS, CK
    ZHANG, DE
    TENEN, DG
    [J]. BLOOD, 1995, 85 (10) : 2918 - 2928
  • [8] A NOVEL INITIATOR/PROMOTER ELEMENT WITHIN THE CD45 UPSTREAM REGION
    DIMARTINO, JF
    HAYES, P
    SAGA, Y
    LEE, JS
    [J]. INTERNATIONAL IMMUNOLOGY, 1994, 6 (08) : 1279 - 1283
  • [9] Fialkow L, 1997, J IMMUNOL, V158, P5409
  • [10] HALL LR, 1988, J IMMUNOL, V141, P2781